Jocelyn Aspa

Jocelyn obtained her diploma in journalism from Langara College in April 2016, just prior to joining INN as a staff writer for the resource sector. Since then, Jocelyn has shifted to covering the life science space and has become managing editor for INN's technology, cannabis and life science divisions. Jocelyn is passionate about niche topics within the life science sector and enjoys shedding light on companies focused on unmet clinical needs.

Prior to joining INN, Jocelyn interned at the Georgia Straight and blogged about the Vancouver Canucks. Before following her career in journalism, Jocelyn spent several years working in law firms. She thrives off the knowledge her background brings to her reporting.

jaspa@investingnews.com

Articles

Pharmaceutical Industry Overview: Top International Regions for Drug Companies

The pharmaceutical industry is concentrated in the US and Europe, and the 10 biggest drug companies are located in those...

July 23rd, 2019

resTORbio Completes Early Enrollment of Phase 3 PROTECTOR 1 Trial with RTB101

resTORbio (NASDAQ:TORC) has announced it has finished enrolling patients in the Phase 3 PROTECTOR 1 trial ahead of schedule. As...

July 23rd, 2019

Cytokinetics Granted European Orphan Designation for Reldesemtiv to Treat Spinal Musclar Atrophy

Cytokinetics (NASDAQ:CYTK) has announced that the European Medicines Agency (EMA) has granted the company orphan medicinal product designation to reldesemtiv...

July 23rd, 2019

Diffusion Pharmaceuticals Reports Safety Data for Phase 3 INTACT Study in Glioblastoma Patients

Diffusion Pharmaceuticals (NASDAQ:DFFN) has announced safety data results in its Phase 3 clinical trial of trans sodium crocetinate in inoperable...

July 23rd, 2019

La Jolla Pharmaceutical Company Receives Orphan Designation from FDA for LJPC-0118

La Jolla Pharmaceutical (NASDAQ:LJPC) has announced that the US Food and Drug Administration (FDA) has granted the company orphan drug...

July 23rd, 2019

What is Genetics Investing?

Genetics investing drives research that may ultimately prevent major illnesses. That makes it one of the most important life science...

July 22nd, 2019

Salarius Pharmaceuticals Enrolls First Patient in a Phase 1 Clinical Study of its Novel Inhibitor

Salarius Pharmaceuticals (NASDAQ:SLRX) has announced it has enrolled the first patient in its Phase 1 clinical study of its lead...

July 22nd, 2019